Ramosetron

Overview

Ramosetron (INN) is a serotonin 5-HT₃ receptor antagonist for the treatment of nausea and vomiting.^[1] Ramosetron is also indicated for a treatment of “diarrhea-predominant irritable bowel syndrome in males”.^[2] In India it is marketed under the brand name of “IBset”.

It is only licensed for use in Japan and selected Southeast Asian countries. It is commonly sold under the tradename Nasea and in India as Nozia (300 mcg/ml Inj. & 100 mcg Tab.) ^[3]

References

↑ Fujii Y, Saitoh Y, Tanaka H, Toyooka H (2000). “Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery”. Anesth. Analg. 90 (2): 472–5. doi:10.1097/00000539-200002000-00043. PMID 10648342. Unknown parameter |month= ignored (help)
↑ http://www.astellas.com/en/corporate/news/detail/astellas-launches-irribow-for.html
↑ Abriged prescribing information – Nasea (MIMS Philippines). Retrieved on June 13, 2008.

Template:5-HT3 antagonists

[1] Fujii Y, Saitoh Y, Tanaka H, Toyooka H (2000). “Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery”. Anesth. Analg. 90 (2): 472–5. doi:10.1097/00000539-200002000-00043. PMID 10648342. Unknown parameter |month= ignored (help)

[2] ttp://www.astellas.com/en/corporate/news/detail/astellas-launches-irribow-for.html

[3] Abriged prescribing information – Nasea (MIMS Philippines). Retrieved on June 13, 2008.

[1]

[2]

[3]

Ramosetron

Overview

References

Looking for the patient version?